Outcome of Board Meeting

Date: 28th October 2026 National Stock Exchange of India Limited BSE Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: Outcome of Board Meeting held on 28th October 2026 Ref: Regulation 30(6) of the SEBI Listing Regulations, 2015 Dear Sir/Ma’am, This is to inform you that the Board of Directors of the Company, at its meeting held on Wednesday, 28th October 2026, has inter alia transacted the following businesses: • Considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter and half year ended on 30th September 2026 The Board meeting commenced at 03:10 p.m. and concluded at 04:25 p.m. You are requested to take the above information on record. For Sudeep Pharma Limited Dimple Mehta Company Secretary & Compliance Officer M. No.: F13184 ENCL: A/a CIN: L24231GJ1989PLC013141 Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India. Phone No.: +91 265 2840656, 7624095107 Corporate Office: 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat, India Website: www.sudeeppharma.com, Email ID: mail@sudeepgroup.com B S R and Co 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Chartered Accountants Goregaon (East), Mumbai – 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010 Limited Review Report on unaudited consolidated financial results of Sudeep Pharma Limited for the quarter ended 30 September 2026 and and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Sudeep Pharma Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Sudeep Pharma Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure I to the Statement: 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The Statement includes the financial results of one Subsidiary which has not been reviewed, whose financial results reflect total assets (before consolidation adjustments) of Rs. 10,637.30 lakhs as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 1,229.77 lakhs and Rs. 2,374.95 lakhs, total net profit after tax and total comprehensive income (before consolidation adjustments) of Rs. 237.94 lakhs and Rs 263.71 lakhs, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash flows (net) (before consolidation adjustments) of Rs 1,113.22 lakhs for the period from 1 April 2026 to 30 September 2026 as considered in the Statement. According to the information and explanations given to us by the Parent’s management, this financial results is not material to the Group. Principal Office: 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 3 B S R and Co Limited Review Report (Continued) Sudeep Pharma Limited Our conclusion is not modified in respect of this matter. For B S R and Co Chartered Accountants Firm’s Registration No.:128510W Jeyur Shah Partner Ahmedabad Membership No.: 045754 28 October 2026 UDIN:26045754TJOEZC9679 Page 2 of 3 B S R and Co Limited Review Report (Continued) Sudeep Pharma Limited Annexure I List of entities included in unaudited consolidated financial results. Sr. No Name of component Relationship 1 Sudeep Pharma Limited Parent 2 Sudeep Nutrition Private Limited Wholly owned subsidiary 3 Sudeep Pharma USA Inc. Wholly owned subsidiary 4 Sudeep Pharma B.V Wholly owned subsidiary 5 Sudeep Advanced Materials Wholly owned subsidiary Private Limited 6 Nutrition Supplies & Services Step down subsidiary (Ireland) Limited Page 3 of 3 Sudeep Pharma Limited Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India Phone No.: +91 265 2840656, 7624095107 Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com CIN: L24231GJ1989PLC013141 Statement of unaudited consolidated financial results for the quarter and year to date period ended 30 September 2026 (₹ in Lakhs) Particulars For quarter ended For year to date period ended For year ended 30 September 30 June 2026 30 September 30 September 30 September 2026 2025 2026 2025 31 March 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Income I. Revenue from operations 1 9,669.91 15,827.05 16,266.62 3 5,496.96 2 8,758.37 64,225.80 II. Other income 598.43 544.54 1,016.55 1 ,142.97 1,532.40 2,858.54 III. Total Income (I+II) 20,268.34 16,371.59 1 7,283.17 36,639.93 3 0,290.77 67,084.34 IV. Expenses Cost of material consumed 7 ,137.04 6,880.57 7,047.56 1 4,017.61 1 2,810.46 26,950.46 Change in inventories of finished goods and work-in-progress (185.63) (1,221.49) (954.06) (1,407.12) (2,484.74) (4,219.77) Employee benefits expense 1 ,561.03 1,433.97 1,409.53 2 ,995.00 2,633.24 5,189.03 Finance costs 281.31 2 06.33 228.19 4 87.64 399.12 7 60.46 Depreciation and amortisation expense 537.61 4 00.08 381.14 9 37.69 706.29 1,480.85 Other expenses 3 ,833.73 3,242.87 3,217.44 7 ,076.60 5,865.83 14,115.87 Total Expenses (IV) 13,165.09 10,942.33 1 1,329.80 24 [Showing first 8,000 characters — download PDF for full document]